Estimands for Clinical Effectiveness of Risk-Reducing Early Salpingectomy in Women With High Risk of Ovarian Cancer

Key Points Question What estimands are most useful for the study of clinical effectiveness of risk-reducing early salpingectomy (RRES) from prospective cohort studies? Findings This comparative effectiveness study of 889 women used estimand and analysis options to evaluate clinical effectiveness of RRES with delayed oophorectomy, using initial data from the PROTECTOR cohort study. The preferred estimand outcome was ovarian cancer incidence after surgery, and the primary target measure was proportion of cancers prevented by RRES vs no surgery with superiority testing. Meaning This estimand differs from those in other ongoing clinical effectiveness studies and suggests a feasible recruitment target for evaluating clinical effectiveness in the PROTECTOR cohort study.

• Publication year

  2025

• Venue

  JAMA Network Open

• Publication date

  2025-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamanetworkopen.2025.32195PMID 40956577PMCID 12441877
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The estimands framework: a primer on the ICH E9(R1) addendum

  2024cited by this paper
• BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial

  2024cited by this paper
• BRCA testing launched for people of Jewish ancestry in England.

  2024cited by this paper
• The NHS England Jewish BRCA Testing Programme: overview after first year of implementation (2023–2024)

  2024cited by this paper
• Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer

  2024cited by this paper
• TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol

  2023cited by this paper
• Carrier screening program for BRCA1/BRCA2 pathogenic variants among Ashkenazi Jewish women in Israel: An observational study

  2023cited by this paper
• Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature.

  2023cited by this paper
• High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors

  2023cited by this paper
• Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review

  2023cited by this paper
• “It was a no-brainer”: A qualitative study of factors driving previvors’ decision-making when considering risk-reducing salpingectomy with delayed oophorectomy

  2022cited by this paper
• Population‐based genetic testing for cancer susceptibility genes: quo vadis?

  2022cited by this paper
• NRG-CC008: A nonrandomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers [SOROCk].

  2022cited by this paper
• Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence

  2022cited by this paper
• Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause

  2021cited by this paper
• Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.

  2021cited by this paper
• Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial

  2021cited by this paper
• Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial

  2020cited by this paper
• Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.

  2020cited by this paper
• Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis

  2020cited by this paper
• Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study

  2020cited by this paper
• Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels

  2020cited by this paper
• Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors

  2020cited by this paper
• Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study

  2020cited by this paper
• Risk‐reducing early salpingectomy and delayed oophorectomy as a two‐staged alternative for primary prevention of ovarian cancer in women at increased risk: a commentary

  2019cited by this paper
• Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions

  2019cited by this paper
• The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma.

  2019cited by this paper
• Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.

  2018cited by this paper
• The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents.

  2018cited by this paper
• High grade serous ovarian carcinomas originate in the fallopian tube

  2017cited by this paper
• Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

  2017cited by this paper
• Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK

  2015cited by this paper
• Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study

  2015cited by this paper
• Ovarian cancer risk after salpingectomy: a nationwide population-based study.

  2015cited by this paper
• Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later.

  2014cited by this paper
• Long-Term Mortality Associated With Oophorectomy Compared With Ovarian Conservation in the Nurses' Health Study

  2013cited by this paper
• Factors influencing uptake and timing of risk reducing salpingo‐oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis

  2012cited by this paper
• Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

  2010cited by this paper
• Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses’ Health Study

  2009cited by this paper
• Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.

  2009cited by this paper
• The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.

  2006cited by this paper

• Errors in Abstract and Methods

  2025cites this paper